



King's Research Portal

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Roney, C. H., Sim, I., Yu, J., Beach, M., Mehta, A., Solis-Lemus, J. A., Kotadia, I., Whitaker, J., Corrado, C., Rzeghi, O., Vigmond, E., Narayan, S. M., O'Neill, M., Williams, S. E., & Niederer, S. A. (2022). Predicting atrial fibrillation recurrence by combining population data and virtual cohorts of patient-specific left atrial models. *Circulation. Arrhythmia and electrophysiology*. Advance online publication.

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Predicting Atrial Fibrillation Recurrence by Combining Population Data and Virtual Cohorts of Patient-Specific Left Atrial Models

Caroline H. Roney¹ PhD; Iain Sim¹ MBBS; Jin Yu¹ BEng; Marianne Beach¹ BSc; Arihant Mehta¹ BSc; Jose Alonso Solis-Lemus¹ PhD; Irum Kotadia, MBBS; John Whitaker¹ BCH, BM; Cesare Corrado, PhD; Orod Razeghi¹ PhD; Edward Vigmond¹ PhD; Sanjiv M. Narayan¹ MD, PhD; Mark O'Neill¹ MBChB; Steven E. Williams¹ MBChB, PhD; Steven A. Niederer¹ PhD

BACKGROUND: Current ablation therapy for atrial fibrillation is suboptimal, and long-term response is challenging to predict. Clinical trials identify bedside properties that provide only modest prediction of long-term response in populations, while patient-specific models in small cohorts primarily explain acute response to ablation. We aimed to predict long-term atrial fibrillation recurrence after ablation in large cohorts, by using machine learning to complement biophysical simulations by encoding more interindividual variability.

METHODS: Patient-specific models were constructed for 100 atrial fibrillation patients (43 paroxysmal, 41 persistent, and 16 long-standing persistent), undergoing first ablation. Patients were followed for 1 year using ambulatory ECG monitoring. Each patient-specific biophysical model combined differing fibrosis patterns, fiber orientation maps, electrical properties, and ablation patterns to capture uncertainty in atrial properties and to test the ability of the tissue to sustain fibrillation. These simulation stress tests of different model variants were postprocessed to calculate atrial fibrillation simulation metrics. Machine learning classifiers were trained to predict atrial fibrillation recurrence using features from the patient history, imaging, and atrial fibrillation simulation metrics.

RESULTS: We performed 1100 atrial fibrillation ablation simulations across 100 patient-specific models. Models based on simulation stress tests alone showed a maximum accuracy of 0.63 for predicting long-term fibrillation recurrence. Classifiers trained to history, imaging, and simulation stress tests (average 10-fold cross-validation area under the curve, 0.85 ± 0.09 ; recall, 0.80 ± 0.13 ; precision, 0.74 ± 0.13) outperformed those trained to history and imaging (area under the curve, 0.66 ± 0.17) or history alone (area under the curve, 0.61 ± 0.14).

CONCLUSION: A novel computational pipeline accurately predicted long-term atrial fibrillation recurrence in individual patients by combining outcome data with patient-specific acute simulation response. This technique could help to personalize selection for atrial fibrillation ablation.

GRAPHIC ABSTRACT: A graphic abstract is available for this article.

Key Words atrial fibrillation ■ benchmarking ■ exercise test ■ machine learning ■ uncertainty

Radiofrequency catheter ablation therapy is recommended in symptomatic drug refractory atrial fibrillation patients. Atrial fibrillation ablation

therapy ranges from pulmonary vein isolation to more extensive ablation strategies consisting of pulmonary vein isolation together with multiple additional lesions.

Correspondence to: Steven A. Niederer, PhD, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. Email stevan.niederer@kcl.ac.uk

This article was sent to Andrew E. Epstein, MD, Guest Editor, for review by expert referees, editorial decision, and final disposition.

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCEP.121.010253>.

For Sources of Funding and Disclosures, see page 101.

© 2022 The Authors. *Circulation: Arrhythmia and Electrophysiology* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Circulation: Arrhythmia and Electrophysiology is available at www.ahajournals.org/journal/circep

WHAT IS KNOWN?

- Current ablation therapy for atrial fibrillation is sub-optimal, and long-term response is challenging to predict.
- Clinical trials identify bedside properties that provide only modest prediction of long-term response in populations, while patient-specific models in small cohorts primarily explain acute response to ablation.
- Identifying optimal ablation approaches for individual patients has the potential to improve safety, inform patient selection, and decrease time and cost for procedures.

WHAT THE STUDY ADDS

- A novel computational pipeline to predict long-term atrial fibrillation recurrence in individual patients by combining outcome data with patient-specific acute simulation response.
- Including biophysical simulations metrics improved classifier performance; classifiers trained to history, imaging, and simulation metrics outperformed those trained to history and imaging or history alone.
- Our technique could help to personalize selection for atrial fibrillation ablation.

Nonstandard Abbreviations and Acronyms

AUC	area under the curve
DECAAF	Delayed-Enhancement MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation
MRI	magnetic resonance imaging
ROC	receiver operating characteristic

Atrial fibrillation patients represent a diverse population requiring a range of different treatment approaches; no single approach is right for all patients, with suboptimal success from pulmonary vein isolation of 55% to 75% at 1.5 years.¹ Identifying a priori optimal ablation approaches for individual patients has the potential to improve safety, inform patient selection, and decrease time and cost for procedures.

Large clinical trials evaluate standard ablation strategies to provide evidence on long-term treatment efficacy for the average patient in a cohort and to derive risk scores for estimating a patient's risk of atrial fibrillation recurrence.²⁻⁵ However, such trials have provided only modest prediction using demographic information, imaging metrics,⁴ acute atrial fibrillation termination,⁶ or in multivariate regression analysis. Moreover, it is not clear how to apply these population data to an individual patient. As an emerging approach, patient-specific biophysical modeling studies enable

simulation and comparison of multiple ablation approaches in a single patient⁷⁻⁹ but have largely been applied to small cohorts of relatively homogeneous patients,¹⁰ and it is unclear how to generalize such models for general clinical use.

We developed a novel computational approach to predict long-term response after ablation in large cohorts, by using machine learning to combine patient-specific models of atrial fibrillation, derived metrics of atrial fibrillation physiology, clinical demographics, and imaging data. We captured unknowns in patient properties such as type of fibrotic remodeling, fiber field, and electrical properties by performing a series of simulation model variant stress tests to evaluate the susceptibility of the atrial substrate to sustained atrial fibrillation. In this work, we aimed to (1) generate comprehensive patient-specific atrial fibrillation signatures from multiple biophysical simulation model variant stress tests for a cohort of 100 patients and (2) train a machine learning classifier to predict long-term ablation outcome from this patient-specific signature.

METHODS

The Methods are briefly described here with full details in the [Supplemental Material](#). We have irreversibly anonymized the 100 models and made these available at <https://cemrg.com/models.html>.

Patient Cohort

Cardiac magnetic resonance imaging (MRI) data were processed for 43 paroxysmal atrial fibrillation, 41 persistent atrial fibrillation, and 16 long-standing persistent atrial fibrillation patients undergoing imaging at St Thomas' Hospital to create a total of 100 patient-specific models. Ethical approval was granted by the regional ethics committee (17/LO/0150 and 15/LO/1803), and subjects gave informed consent. The inclusion criteria for this study were first-time atrial fibrillation ablation patients with no previous left atrial ablation who had late-gadolinium enhancement MRI performed at the clinician's discretion for preprocedural planning. At St Thomas' Hospital, ablation treatment is indicated for patients with symptoms of atrial fibrillation who have failed a single antiarrhythmic agent. These patients underwent first-time catheter ablation therapy for atrial fibrillation, which consisted of pulmonary vein isolation alone or with the addition of ablation lines (mitral or roof) or posterior box isolation ablation.¹¹ Patients were followed up for 1 year after their ablation procedure as per routine assessment at our institution. This consisted of 2 to 4 appointments over the year with AF symptom assessment, 12-lead ECG recordings, and ambulatory monitoring on the basis of patient symptoms. Atrial fibrillation recurrence was assessed following a 3-month blanking period. The Table details patient demographics, ablation therapy approach, and antiarrhythmic drug therapy, analyzed by atrial fibrillation recurrence.

The schematic in Figure 1 shows an overview of the methodology used for predicting clinical outcome by combining patient-specific biophysical simulation stress tests and population data through machine learning techniques.

Table. Clinical Metrics Analyzed by AF Recurrence

Grouped by AF recurrence	No AF recurrence	AF recurrence	P value
n	65	34	
BMI	29.1 (4.6)	28.2 (4.9)	0.391
LVEF	59.7 (7.2)	57.0 (8.4)	0.116
Age at ablation, y	61.3 (9.0)	58.8 (13.1)	0.315
CHA ₂ DS ₂ -VASc	1.4 (1.4)	1.2 (1.3)	0.638
Female sex	21 (32.3)	7 (20.6)	0.320
Congestive heart failure	8 (12.3)	3 (8.8)	0.744
Hypertension	19 (29.2)	13 (38.2)	0.494
Diabetes	5 (7.7)	1 (2.9)	0.661
History of stroke/TIA	3 (4.6)	2 (5.9)	0.445
Coronary disease	6 (9.2)	4 (11.8)	0.733
AF type			
Paroxysmal	29 (44.6)	13 (38.2)	0.712
Persistent	25 (38.5)	16 (47.1)	
Long-standing	11 (16.9)	5 (14.7)	
Ablation type			
PVI only	41 (63.1)	15 (44.1)	0.212
PVI+lines	3 (4.6)	1 (2.9)	
PVI+box	17 (26.2)	16 (47.1)	
PVI+box+lines	4 (6.2)	2 (5.9)	
Rhythm control			
Amiodarone	13 (20.0)	7 (20.6)	0.511
Flecainide	8 (12.3)	7 (20.6)	
Sotalolol	2 (3.1)	3 (8.8)	
None	29 (44.6)	13 (38.2)	
Unknown	13 (20.0)	4 (11.8)	
Rate control			
β-Blockers	23 (35.4)	17 (50.0)	0.556
CCBs	5 (7.7)	1 (2.9)	
Digoxin	2 (3.1)		
BB+CCB	3 (4.6)	1 (2.9)	
BB+digoxin	2 (3.1)		
CCB+digoxin	1 (1.5)		
None	16 (24.6)	11 (32.4)	
Unknown	13 (20.0)	4 (11.8)	

Results are given as the mean with the SD in brackets (BMI–CHA₂DS₂-VASc) or number with the percentage in brackets (female sex–rate control). P values refer to *t* test or χ^2 test results. AF indicates atrial fibrillation; BB, beta blocker; BMI, body mass index; CCB, calcium channel blocker; and PVI, pulmonary vein isolation.

Simulated Atrial Fibrillation Model Variant Stress Tests

Models were constructed using the steps given in the [Supplemental Material](#). Simulation model variant stress tests were designed to probe the uncertainty in atrial properties and test the ability of the substrate to sustain atrial fibrillation before and after varying ablation lesion sets. Acute response to simulated ablation was tested for 11 different simulation setups shown in Figure 2. The baseline setup, shown in the light blue box and numbered (1) in Figure 2, included

combination fibrotic remodeling (interstitial fibrosis with conductivity and ionic changes) together with the baseline choice for the following properties: diffusion tensor MRI fiber field, pulmonary vein isolation lesion set, atrial fibrillation initiation map, and effective refractory period. To evaluate the effects of uncertainty in each component of the atrial substrate separately, we varied the properties of the baseline atrial model individually, while leaving the other properties of the model fixed at the baseline values. The properties we varied were the type of fibrotic remodeling (tests 1–4), the diffusion tensor MRI fiber map (5 and 6), the ablation lesion size (7), the initiation protocol (8 and 9), and the electrical properties (10 and 11). Preablation arrhythmia simulations (15 s) were analyzed for setups 1 to 4; postablation arrhythmia simulations (2 s) were analyzed for setups 1 to 11. More details on each setup are given in the [Supplemental Material](#).

Machine Learning Classifiers to Predict Atrial Fibrillation Recurrence on Long-Term Follow-Up

Machine learning classifiers were trained to map clinical data to long-term outcome. Specifically, classifiers were trained to predict binary clinical atrial fibrillation recurrence for 3 clinical data sets: (1) simulation, imaging, and patient history; (2) imaging and patient history; and (3) patient history alone. Further details on the metrics included in each classifier are given in the [Supplemental Methods](#).

Statistical Analysis

For each data set (1–3), the following machine learning classifiers were compared: K nearest neighbors, support vector machine, random forest, and logistic regression. Each classifier was trained to each data set either with or without principal component analysis preprocessing, with the number of components chosen to retain 95% of the variance. The accuracy, recall, precision, and receiver operating characteristic area under the curve values were compared for each combination of data set and classifier, with and without principal component analysis. For each data set (1–3), the classifier with the largest receiver operating characteristic area under the curve value was selected. Further details are given in the [Supplemental Methods](#).

RESULTS

Cohort Properties

Follow-up data were available for 99 of the 100 cases. AF recurred in the first year after ablation (following a 3-month blanking period) for 34 of the patients, with a mean recurrence time of 189±95 days. None of the clinical metrics considered were significantly different between cases with or without arrhythmia recurrence (Table).

Imaging Metrics Related to Atrial Fibrillation Recurrence

The average visual fibrosis score was higher for the atrial fibrillation recurrence group, but this did not reach




Figure 1. Schematic methodology for using machine learning to combine biophysical simulation stress tests for acute simulation responses with population data to predict long-term atrial fibrillation (AF) recurrence.

Clinical imaging data were used to construct a cohort of patient-specific models. Biophysical simulation stress tests with different types of fibrosis, fiber maps, AF induction protocols, effective refractory period (ERP) values, and pulmonary vein isolation (PVI) sizes were used to test AF inducibility. These simulation stress test metrics were combined with imaging and patient history metrics to produce a patient-specific signature. This was repeated to produce a population of models. Machine learning classifiers were trained across this population to predict clinical outcome from patient-specific signature. Classifiers used either (A) simulation, imaging, and patient history metrics; (B) imaging and patient history metrics; or (C) patient history metrics. DT-MRI indicates diffusion tensor magnetic resonance imaging.

significance ($P=0.169$). Figure 3 shows that, when defining fibrotic regions with an image intensity ratio threshold of 1.22, the calculated imaging metrics were not significantly different between the groups with and without atrial fibrillation recurrence. These include (1) total atrial surface area (152.0 ± 30.5 versus 154.8 ± 27.2 cm²; $P=0.55$), (2) pulmonary vein surface area (27.8 ± 8.6 versus 28.2 ± 7.0 cm²; $P=0.58$), (3) fibrosis surface area (32.4 ± 24.2 versus 31.9 ± 22.0 cm²; $P=0.94$), and (4) area of fibrosis in the pulmonary veins (8.6 ± 6.3 versus 6.3 ± 6.6 cm²; $P=0.72$). The median fibrosis surface areas by visual fibrosis category were as follows: healthy, 23.7 cm²; mild, 18.2 cm²; moderate, 33.1 cm²; and severe, 41.6 cm².

Relating Acute Atrial Fibrillation Termination by Simulated Ablation to Long-Term Recurrence

Prediction accuracy of the single acute simulation stress tests for predicting long-term clinical atrial fibrillation recurrence was in the range: 0.38 to 0.63 (using a threshold dominant frequency of 4.7 Hz to define simulations with atrial fibrillation). Figure 4 shows transmembrane potential maps 2 s after pulmonary vein isolation

ablation for the interstitial fibrosis setup (simulation stress test setup number 3): 40 of 65 cases of no clinical recurrence were classified correctly, and 20 of 34 cases of clinical recurrence were classified correctly using the acute simulation outcome.

In general, acute simulation outcome stress tests did not differentiate between clinical outcomes. Table S1 gives all the simulation metrics by group (without or with clinical atrial fibrillation recurrence). The table first lists properties of the 15-s atrial fibrillation simulations before pulmonary vein isolation was applied for the different fibrosis type setups 1 to 4, as follows: mean number of phase singularities, phase singularity area, and pulmonary vein phase singularity area. These are followed by the outcome variables given as dominant frequency (atrial rate) for the simulations in the 2 s after pulmonary vein isolation was applied for setups 1 to 11. For dominant frequency, there was a trend between groups without and with atrial fibrillation recurrence for simulations including interstitial fibrosis (setup number 3: 2.6 ± 2.5 versus 3.4 ± 2.3 Hz; $P=0.11$) and no fibrotic remodeling (setup number 4: 3.2 ± 2.5 versus 4.1 ± 2.1 Hz; $P=0.095$). Other simulation metrics were not significantly different.




Figure 2. Simulation model variant stress tests.

The choices indicated by the light blue background represent the baseline model. Other setups include the baseline model setup with a variation in one of the following model features: (setups: 2–4) fibrosis type, (5 and 6) diffusion tensor magnetic resonance imaging (DT-MRI) fiber maps, (7) pulmonary vein isolation size (PVI), (8 and 9) atrial fibrillation (AF) initiation map, (10 and 11) effective refractory period (ERP) values.

Prediction of Atrial Fibrillation Recurrence by Combining Population Data and Patient-Specific Modeling

Figure 5 shows receiver operating characteristic curves for optimal classifiers constructed from (1) simulation, imaging, and patient history data; (2) imaging and patient history data; and (3) patient history data.

For the simulation, imaging, and patient history classifier (Figure 5A), the optimal classifier was support vector machine with principal component analysis: receiver operating characteristic (ROC) area under the curve (AUC), 0.85 ± 0.09 ; accuracy, 0.74 ± 0.13 ; recall, 0.80 ± 0.12 ; and precision, 0.72 ± 0.15 . Other classifier ROC AUC values were as follows: K nearest neighbor, 0.85 ± 0.09 ; random forest, 0.77 ± 0.14 ; and logistic regression, 0.59 ± 0.12 .

Conversely, less inclusive classifiers were less predictive. Figure 5B shows results for the imaging and patient history classifier; the optimal classifier in this case was K nearest neighbor with principal component analysis: ROC AUC, 0.66 ± 0.17 ; accuracy, 0.68 ± 0.07 ;

recall, 0.57 ± 0.34 ; and precision, 0.58 ± 0.38 . For the patient history classifier shown in Figure 5C, the random forest classifier was optimal: ROC AUC, 0.61 ± 0.14 ; accuracy, 0.64 ± 0.14 ; recall, 0.46 ± 0.24 ; and precision, 0.46 ± 0.28 .

DISCUSSION

Main Findings

We present a novel personalized digital approach that predicted response to atrial fibrillation ablation in individual patients when patient-specific geometry and simulations were combined with clinical data. The foundation for this approach demonstrates a novel computational pipeline that can be tuned to individual patient features, which takes into account likely physiological interactions between clinical demographics and the natural history of atrial fibrillation post-ablation and which can be readily scaled to personalize therapy. Notably, we found that predicting atrial fibrillation ablation response was suboptimal based on patient history or imaging data alone. Adding patient-specific simulations significantly improved prediction accuracy. This is the largest atrial fibrillation simulation study to date, demonstrating that patient-specific simulation can be scaled to generate virtual cohorts that can predict patient-level outcomes and could potentially be used to design optimal procedures for each individual a priori.

Comparison With Other Imaging Predictors of Atrial Fibrillation Recurrence

Translating from average results to predictions for individual patients using standard risk scores is challenging. Previous studies have assessed the utility of anatomic and imaging metrics calculated from populations of images for predicting atrial fibrillation recurrence. For example, the DECAAF clinical trial (Delayed-Enhancement MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation) indicated that the degree of atrial late-gadolinium enhancement was independently associated with atrial fibrillation recurrence following catheter ablation in a cohort of 260 patients.¹² We did not find this in our study; however, we used a smaller cohort with both paroxysmal and persistent atrial fibrillation patients. For anatomic metric analysis, Varela et al² analyzed left atrial anatomy from MRI across a cohort of 144 patients to predict atrial fibrillation recurrence using vertical asymmetry together with left atrial sphericity to give an area under the ROC curve of 0.71. Bratt et al³ demonstrated that atrial volume is a good predictor of atrial fibrillation recurrence, with an ROC AUC of 0.77. They automatically segmented the left atrial body from computed tomography scans using deep learning and




Figure 3. Simple imaging metrics do not vary with atrial fibrillation (AF) recurrence.

A, Total surface area ($P=0.55$). **B**, Pulmonary vein (PV) surface area ($P=0.58$). **C**, Total fibrosis surface area (thresholded at image intensity ratio >1.22 ; $P=0.94$). **D**, Total fibrosis surface area in the PV regions ($P=0.72$).

showed that atrial volume is an independent predictor of atrial fibrillation, with an age-adjusted relative risk of 2.9.³ Costa et al⁴ showed that left atrial volume is more important than atrial fibrillation type for predicting atrial fibrillation recurrence following pulmonary vein isolation. In contrast to these studies, Ebersberger et al¹³ showed no association between pulmonary vein properties or left atrial anatomic or functional properties measured on computed tomography and early atrial fibrillation recurrence at 3 to 4 months post-ablation. Our study also found that simple imaging metrics are not predictive of atrial fibrillation recurrence. However, we did not include vertical asymmetry or volume in this assessment, and we used MRI rather than computed tomography data.¹⁴

Computed tomography data also provide information on epicardial adipose tissue content, which may affect atrial fibrillation maintenance. Nalliah et al¹⁵ investigated the mechanisms for how epicardial adipose tissue affects atrial fibrillation, showing that higher adipose tissue is associated with slower conduction, higher degrees of electrogram fractionation, increased fibrosis, and increased lateralization of connexin40 gap junctional protein. Further to this, El Mahdiui et al¹⁵ found that posterior left atrial adipose tissue attenuation is predictive of atrial fibrillation recurrence post-ablation.

Comparison With Other Simulation Predictors of Atrial Fibrillation Recurrence

Shade et al¹⁰ combined modeling and machine learning to predict atrial fibrillation recurrence in a cohort of 32 patients with paroxysmal atrial fibrillation. This study extends their elegant work by testing a range of unknowns in the substrate, enabling a greater degree of personalization through a simulation stress test approach, and by testing the effects of ablation approach, in a larger cohort of less homogeneous paroxysmal and persistent atrial fibrillation patients. The simulation stress test approach used in our study is analogous to a rigorous clinical test of postpulmonary vein isolation atrial fibrillation inducibility, which provided high specificity for atrial fibrillation recurrence in a large meta-analysis¹⁶ although it is difficult to apply due to practical constraints. We used a technique of initiating reentry through seeding phase singularities in multiple different locations. We applied this technique to initiate atrial fibrillation in setups 1 to 4 before ablation and also to test inducibility after pulmonary vein isolation for setups 1 to 11. This technique is more computationally efficient but may be less clinically realistic than the initiation technique of rapid pacing from




Figure 4. Acute response to pulmonary vein isolation ablation for simulations incorporating interstitial fibrosis grouped by clinical atrial fibrillation (AF) recurrence.

Transmembrane potential plots are shown 2 s after pulmonary vein isolation ablation for the interstitial fibrosis simulation setup. The first 65 cases had no clinical AF recurrence, while the bottom 34 had AF recurrence. The background color indicates whether acute simulation response was considered successful (termination to sinus rhythm or organized nonfibrillatory rhythms) in white or AF is sustained in gray.

multiple locations performed by Boyle et al.⁹ Recently, Azzolin et al¹⁷ proposed a technique that paces at the end of the effective refractory period to initiate atrial fibrillation and compared this to rapid pacing or using a phase distribution method to show that their method induced a larger variety of reentry scenarios, with a marginal increase in simulation time. More extensive inducibility testing protocols, such as those proposed by Boyle et al⁹ and Azzolin et al,¹⁷ could be used to identify further reentry areas and as additional features for the classifiers, which may increase the predictive accuracy.

Limitations

There are multiple factors we did not include in the simulation model including the effects of ectopic beats on arrhythmia recurrence. We did not model the pulmonary vein isolation ablation lesions applied clinically but rather simulated these lesions as wide area circumferential ablation at a fixed distance from the left atrial/pulmonary vein junctions. Further, these lesion sets may be incomplete with gaps of surviving or recovered tissue, which would affect acute simulation outcome. We only simulated pulmonary vein isolation and did not include




Figure 5. Receiver operating characteristic (ROC) curves for simulation, imaging, and patient history classifiers.

ROC curves for classifiers constructed from (A) simulation, imaging, and patient history data (support vector machine classifier); (B) imaging and patient history data (K nearest neighbor classifier); and (C) patient history data alone (random forest classifier). The gray area indicates ± 1 SD calculated from 10-fold cross-validation. AUC indicates area under the curve.

patient-specific lesion sets. We considered follow-up data for 1 year post-ablation only. The choice of image intensity threshold used for modeling scar will influence the imaging and simulation metrics. We used rule-based calibration of conduction velocity based on image intensities, but there is uncertainty associated with this prediction. We do not have validation of this rule-based inclusion of patient-specific electrophysiology across the data set used in the current study.¹⁸ We only included the left atrium in our simulations; however, performing biatrial simulations^{19–21} may improve the predictive accuracy of the classifier. Adding features derived from the 12-lead ECG provides additional information on the atria and could further improve the classifier.⁷ Overall, further work is required to choose the optimal simulation stress test setup. The optimal classifier properties for screening for likely atrial fibrillation recurrence will be considered in future studies.

Conclusions

We present a novel computational pipeline that accurately predicted atrial fibrillation recurrence following ablation therapy in individual patients by combining outcome data with patient-specific acute simulation response. This technique could help to personalize selection for atrial fibrillation ablation and could be evaluated through a prospective clinical trial.

ARTICLE INFORMATION

Received June 1, 2021; accepted January 3, 2022.

Affiliations

School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (C.H.R., I.S., J.Y., M.B., A.M., J.A.S.-L., I.K., J.W., C.C., O.R., M.O., S.E.W., S.A.N.). School of Engineering and Materials Science, Queen Mary University of London, United Kingdom (C.H.R.). The Department of Internal Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (J.W.). IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, France (E.V.). Univ. Bordeaux, IMB, UMR 5251, F-33400 Talence, France (E.V.). Department of Medicine and Cardiovascular Institute, Stanford University, Palo Alto, CA (S.M.N.). Centre for Cardiovascular Science, College of Medicine and Veterinary Medicine, University of Edinburgh (S.E.W.).

Sources of Funding

Dr Roney acknowledges a Medical Research Council Skills Development Fellowship (MR/S015086/1). Dr Niederer acknowledges support from the UK Engineering and Physical Sciences Research Council (EP/M012492/1, NS/A000049/1, and EP/P01268X/1), The British Heart Foundation (PG/15/91/31812 and PG/13/37/30280), and Kings Health Partners London National Institute for Health Research (NIHR) Biomedical Research Centre. This work was supported by the Wellcome/EPSCRC Centre for Medical Engineering (WT 203148/Z/16/Z). This study received financial support from the French Government as part of the "Investments of the Future" program managed by the National Research Agency (ANR), grant reference ANR-10-IAHU-04. Dr Narayan acknowledges support from NIH R01 HL149134 (Machine Learning in Atrial Fibrillation) and R01 HL83359 (Dynamics of Atrial Fibrillation). Dr Williams acknowledges support from a British Heart Foundation Intermediate Clinical Research Fellowship (FS/20/26/34952).

Disclosures

M. O'Neill has received research support and honoraria from Biosense Webster and has received consultation fees from Medtronic, Biosense Webster, St. Jude/

Abbott, and Siemens. Dr Williams has received research support from Biosense Webster and EPD Solutions and consulting fees from Imricor Medical Systems. Dr Niederer reports intellectual property rights from King's College London and support from Siemens, Pfizer, EBR Systems, Boston Scientific, and Abbott. Dr Narayan reports consulting from Beyond.ai, Inc, TDK, Inc, Up to Date, Abbott Laboratories, and the American College of Cardiology Foundation and intellectual property rights from the University of California Regents and Stanford University. The other authors report no conflicts.

Supplemental Material

Supplemental Methods

Table S1

Videos S1 and S2

References^{22–48}

REFERENCES

- Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, et al; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med*. 2015;372:1812–1822. doi: 10.1056/NEJMoa1408288
- Varela M, Bisbal F, Zacur E, Berruzo A, Aslanidi OV, Mont L, Lamata P. Novel computational analysis of left atrial anatomy improves prediction of atrial fibrillation recurrence after ablation. *Front Physiol*. 2017;8:68. doi: 10.3389/fphys.2017.00068
- Bratt A, Guenther Z, Hahn LD, Kadoch M, Adams PL, Leung ANC, Guo HH. Left atrial volume as a biomarker of atrial fibrillation at routine chest CT: deep learning approach. *Radiol Cardiothorac Imaging*. 2019;1:e190057. doi: 10.1148/ryct.2019190057
- Costa FM, Ferreira AM, Oliveira S, Santos PG, Durazzo A, Carmo P, Santos KR, Cavaco D, Parreira L, Morgado F, et al. Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation. *Int J Cardiol*. 2015;184:56–61. doi: 10.1016/j.ijcard.2015.01.060
- El Mahdiui M, Simon J, Smit JM, Kuneman JH, van Rosendael AR, Steyerberg EW, van der Geest RJ, Száraz L, Herczeg S, Szegedi N, et al. Posterior left atrial adipose tissue attenuation assessed by computed tomography and recurrence of atrial fibrillation after catheter ablation. *Circ Arrhythm Electrophysiol*. 2021;14:e009135. doi: 10.1161/CIRCEP.120.009135
- Kochhäuser S, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, et al; STAR AF II Investigators. Impact of acute atrial fibrillation termination and prolongation of atrial fibrillation cycle length on the outcome of ablation of persistent atrial fibrillation: a substudy of the STAR AF II trial. *Heart Rhythm*. 2017;14:476–483. doi: 10.1016/j.hrthm.2016.12.033
- Luongo G, Azzolin L, Schuler S, Rivolta MW, Almeida TP, Martínez JP, Soriano DC, Luik A, Müller-Edenborn B, Jadidi A, et al. Machine learning enables noninvasive prediction of atrial fibrillation driver location and acute pulmonary vein ablation success using the 12-lead ECG. *Cardiovasc Digit Health J*. 2021;2:126–136. doi: 10.1016/j.cvdhj.2021.03.002
- Roney CH, Beach ML, Mehta AM, Sim I, Corrado C, Bendikis R, Solis-Lemus JA, Razeghi O, Whitaker J, O'Neill L, et al. In silico comparison of left atrial ablation techniques that target the anatomical, structural, and electrical substrates of atrial fibrillation. *Front Physiol*. 2020;11:1145. doi: 10.3389/fphys.2020.572874
- Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, Hakim JB, Murphy MJ, Prakosa A, Zimmerman SL, et al. Computationally guided personalized targeted ablation of persistent atrial fibrillation. *Nat Biomed Eng*. 2019;3:870–879. doi: 10.1038/s41551-019-0437-9
- Shade JK, Ali RL, Basile D, Popescu D, Akhtar T, Marine JE, Spragg DD, Calkins H, Trayanova NA. Preprocedure application of machine learning and mechanistic simulations predicts likelihood of paroxysmal atrial fibrillation recurrence following pulmonary vein isolation. *Circ Arrhythm Electrophysiol*. 2020;13:e008213. doi: 10.1161/CIRCEP.119.008213
- Williams SE, O'Neill L, Roney CH, Julia J, Metzner A, Reißmann B, Mukherjee RK, Sim I, Whitaker J, Wright M, et al. Left atrial effective conduction size predicts atrial fibrillation vulnerability in persistent but not paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol*. 2019;30:1416–1427. doi: 10.1111/jce.13990
- Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation

- catheter ablation: the DECAAF study. *JAMA*. 2014;311:498–506. doi: 10.1001/jama.2014.3
13. Ebersberger U, Bernard ML, Schoepf UJ, Wince WB, Litwin SE, Wang Y, Blanke P, Makowski MR, McQuiston AD, Silverman JR, et al. Cardiac computed tomography for atrial fibrillation patients undergoing ablation: implications for the prediction of early recurrence. *J Thorac Imaging*. 2020;35:186–192. doi: 10.1097/RTI.0000000000000425
 14. Firouznia M, Feeny AK, LaBarbera MA, McHale M, Cantlay C, Kalfas N, Schoenhagen P, Saliba W, Tchou P, Barnard J, et al. Machine learning-derived fractal features of shape and texture of the left atrium and pulmonary veins from cardiac computed tomography scans are associated with risk of recurrence of atrial fibrillation postablation. *Circ Arrhythm Electrophysiol*. 2021;14:e009265. doi: 10.1161/CIRCEP.120.009265
 15. Nalliah CJ, Bell JR, Raaijmakers AJA, Waddell HM, Wells SP, Bernasochi GB, Montgomery MK, Binny S, Watts T, Joshi SB, et al. Epicardial adipose tissue accumulation confers atrial conduction abnormality. *J Am Coll Cardiol*. 2020;76:1197–1211. doi: 10.1016/j.jacc.2020.07.017
 16. Millenaar D, Becker N, Pavlicek V, Wintrich J, Böhm M, Mahfoud F, Ukena C. Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta-analysis. *Pacing Clin Electrophysiol*. 2021;44:667–676. doi: 10.1111/pace.14216
 17. Azzolin L, Schuler S, Dössel O, Loewe A. A reproducible protocol to assess arrhythmia vulnerability in silico: pacing at the end of the effective refractory period. *Front Physiol*. 2021;12:656411. doi: 10.3389/fphys.2021.656411
 18. Deng D, Murphy MJ, Hakim JB, Franceschi WH, Zahid S, Pashkhanloo F, Trayanova NA, Boyle PM. Sensitivity of reentrant driver localization to electrophysiological parameter variability in image-based computational models of persistent atrial fibrillation sustained by a fibrotic substrate. *Chaos*. 2017;27:093932. doi: 10.1063/1.5003340
 19. Roy A, Varela M, Aslanidi O. Image-based computational evaluation of the effects of atrial wall thickness and fibrosis on re-entrant drivers for atrial fibrillation. *Front Physiol*. 2018;9:1352. doi: 10.3389/fphys.2018.01352
 20. Roney CH, Williams SE, Cochet H, Mukherjee RK, O'Neill L, Sim I, Whitaker J, Razeghi O, Klein GJ, Vigmond EJ, et al. Patient-specific simulations predict efficacy of ablation of interatrial connections for treatment of persistent atrial fibrillation. *Europace*. 2018;20:iii55–iii68. doi: 10.1093/europace/euy232
 21. Ali RL, Hakim JB, Boyle PM, Zahid S, Sivasambu B, Marine JE, Calkins H, Trayanova NA, Spragg DD. Arrhythmogenic propensity of the fibrotic substrate after atrial fibrillation ablation: a longitudinal study using magnetic resonance imaging-based atrial models. *Cardiovasc Res*. 2019;115:1757–1765. doi: 10.1093/cvr/cvz083
 22. Sim I, Razeghi O, Karim R, Chubb H, Whitaker J, O'Neill L, Mukherjee RK, Roney CH, Razavi R, Wright M, et al. Reproducibility of atrial fibrosis assessment using CMR imaging and an open source platform. *JACC Cardiovasc Imaging*. 2019;12:2076–2077. doi: 10.1016/j.jcmg.2019.03.027
 23. Cignoni P, Callieri M, Corsini M, Dellepiane M, Ganovelli F, Ranzuglia G. MeshLab: an open-source mesh processing tool. In: 6th Eurographics Italian Chapter Conference 2008 - Proceedings. 2008.
 24. Ahrens J, Geveci B, Law C. ParaView: an end-user tool for large-data visualization. In: *Visualization Handbook*. 2005.
 25. Dapogny C, Dobrzynski C, Frey P. Three-dimensional adaptive domain remeshing, implicit domain meshing, and applications to free and moving boundary problems. *J Comput Phys*. 2014;262:358–378.
 26. Dobrzynski C, Frey P. Anisotropic delaunay mesh adaptation for unsteady simulations. *Proceedings of the 17th IMR 2008*. 2008;177–194.
 27. Roney CH, Pashaei A, Meo M, Dubois R, Boyle PM, Trayanova NA, Cochet H, Niederer SA, Vigmond EJ. Universal atrial coordinates applied to visualisation, registration and construction of patient specific meshes. *Med Image Anal*. 2019;55:65–75. doi: 10.1016/j.media.2019.04.004
 28. Labarthe S, Bayer J, Coudière Y, Henry J, Cochet H, Jais P, Vigmond E. A bilayer model of human atria: mathematical background, construction, and assessment. *Europace*. 2014;16(suppl 4):iv21–iv29.
 29. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. *Cardiovasc Res*. 1999;42:477–489. doi: 10.1016/s0008-6363(99)00034-6
 30. Vigmond EJ, Weber dos Santos R, Prassl AJ, Deo M, Plank G. Solvers for the cardiac bidomain equations. *Prog Biophys Mol Biol*. 2008;96:3–18. doi: 10.1016/j.pbiomolbio.2007.07.012
 31. Roney CH, Bayer JD, Cochet H, Meo M, Dubois R, Jais P, Vigmond EJ. Variability in pulmonary vein electrophysiology and fibrosis determines arrhythmia susceptibility and dynamics. *PLoS Comput Biol*. 2018;14:e1006166. doi: 10.1371/journal.pcbi.1006166
 32. Bayer JD, Roney CH, Pashaei A, Jais P, Vigmond EJ. Novel radiofrequency ablation strategies for terminating atrial fibrillation in the left atrium: a simulation study. *Front Physiol*. 2016;7:108. doi: 10.3389/fphys.2016.00108
 33. Pashkhanloo F, Herzka DA, Ashikaga H, Mori S, Gai N, Bluemke DA, Trayanova NA, McVeigh ER. Myofiber architecture of the human atria as revealed by submillimeter diffusion tensor imaging. *Circ Arrhythm Electrophysiol*. 2016;9:e004133. doi: 10.1161/CIRCEP.116.004133
 34. Beach M, Sim I, Mehta A, Kotadia I, Hare DO, Whitaker J, Solis-lemus JA, Razeghi O, Chiribiri A, Neill MO, et al. Using the universal atrial coordinate system for MRI and electroanatomic data registration in patient-specific left atrial model construction and simulation. *FIMH*. 2021.
 35. Roney CH, Bayer JD, Zahid S, Meo M, Boyle PM, Trayanova NA, Haissaguerre M, Dubois R, Cochet H, Vigmond EJ. Modelling methodology of atrial fibrosis affects rotor dynamics and electrograms. *Europace*. 2016;18(suppl 4):iv146–iv155. doi: 10.1093/europace/euw365
 36. Zahid S, Cochet H, Boyle PM, Schwarz EL, Whyte KN, Vigmond EJ, Dubois R, Hocini M, Haissaguerre M, Jais P, et al. Patient-derived models link re-entrant driver localization in atrial fibrillation to fibrosis spatial pattern. *Cardiovasc Res*. 2016;110:443–454. doi: 10.1093/cvr/cvw073
 37. Spach MS, Heidlage JF, Dolber PC, Barr RC. Mechanism of origin of conduction disturbances in aging human atrial bundles: experimental and model study. *Heart Rhythm*. 2007;4:175–185. doi: 10.1016/j.hrthm.2006.10.023
 38. Costa CM, Campos FO, Prassl AJ, dos Santos RW, Sánchez-Quintana D, Ahammer H, Hofer E, Plank G. An efficient finite element approach for modeling fibrotic clefts in the heart. *IEEE Trans Biomed Eng*. 2014;61:900–910. doi: 10.1109/TBME.2013.2292320
 39. Matene E, Jacquemet V. Fully automated initiation of simulated episodes of atrial arrhythmias. *Europace*. 2012;14 Suppl 5:v17–v24. doi: 10.1093/europace/eus271
 40. Rappel WJ, Zaman JA, Narayan SM. Mechanisms for the termination of atrial fibrillation by localized ablation: computational and clinical studies. *Circ Arrhythm Electrophysiol*. 2015;8:1325–1333. doi: 10.1161/CIRCEP.115.002956
 41. Krummen DE, Bayer JD, Ho J, Ho G, Smetak MR, Clopton P, Trayanova NA, Narayan SM. Mechanisms of human atrial fibrillation initiation: clinical and computational studies of repolarization restitution and activation latency. *Circ Arrhythm Electrophysiol*. 2012;5:1149–1159. doi: 10.1161/CIRCEP.111.969022
 42. Wilhelms M, Hettmann H, Maleckar MM, Koivumäki JT, Dössel O, Seemann G. Benchmarking electrophysiological models of human atrial myocytes. *Front Physiol*. 2012;3:487. doi: 10.3389/fphys.2012.00487
 43. Potse M, Dubé B, Richer J, Vinet A, Gulrajani RM. A comparison of monodomain and bidomain reaction-diffusion models for action potential propagation in the human heart. *IEEE Trans Biomed Eng*. 2006;53(12 pt 1):2425–2435. doi: 10.1109/TBME.2006.880875
 44. Roth BJ. Meandering of spiral waves in anisotropic cardiac tissue. *Phys D: Nonlinear Phenom*. 2001;150:127–136.
 45. Niederer SA, Kerfoot E, Benson AP, Bernabeu MO, Bernus O, Bradley C, Cherry EM, Clayton R, Fenton FH, Garny A, et al. Verification of cardiac tissue electrophysiology simulators using an N-version benchmark. *Philos Trans A Math Phys Eng Sci*. 2011;369:4331–4351. doi: 10.1098/rsta.2011.0139
 46. Roney CH, Bendikar R, Pashkhanloo F, Corrado C, Vigmond EJ, McVeigh ER, Trayanova NA, Niederer SA. Constructing a human atrial fibre atlas. *Ann Biomed Eng*. 2021;49:233–250. doi: 10.1007/s10439-020-02525-w
 47. Varoquaux G, Buitinck L, Louppe G, Grisel O, Pedregosa F, Mueller A. Scikit-learn: machine learning in python. *GetMobile: Mobile Computing and Communications*. 2015;19:29–33.
 48. Pollard TJ, Johnson AEW, Raffa JD, Mark RG. tableone: an open source python package for producing summary statistics for research papers. *JAMIA Open*. 2018;1:26–31. doi: 10.1093/jamiaopen/ooy012